New drug targets 'Undruggable' mutation in deadly pancreatic cancer
NCT ID NCT07303465
Summary
This study is testing an experimental drug called RNK08954 for people with advanced pancreatic cancer that has spread and has a specific genetic change called KRAS G12D. The main goals are to see if the drug is safe and if it can help slow or stop the cancer's growth. It is for adults whose cancer has not responded to other treatments and who have not taken similar KRAS-targeting drugs before.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Tianyinshan Hospital
RECRUITINGNanjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai GoBroad Cancer Hospital China Pharmaccutical University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.